News
The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.
12h
Pharmaceutical Technology on MSNGilead’s Kite scoops in vivo CAR-T specialist Interius for $350m
Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...
Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.
The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...
Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...
CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...
Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results